Adenosine-dependent airway inflammation and hyperresponsiveness in partially adenosine deaminase-deficient mice.
Adenosine is a signaling nucleoside that is elevated in the lungs of asthmatics. We have engineered a mouse model that has elevated levels of adenosine as a result of the partial expression of the enzyme that metabolizes adenosine, adenosine deaminase (ADA). Mice with lowered levels of ADA enzymatic activity were generated by the ectopic expression of an ADA minigene in the gastrointestinal tract of otherwise ADA-deficient mice. These mice developed progressive lung inflammation and damage and died at 4-5 mo of age from respiratory distress. Associated with this phenotype was a progressive increase in lung adenosine levels. Examination of airway physiology at 6 wk of age revealed alterations in airway hyperresponsiveness. This was reversed following the lowering of adenosine levels using ADA enzyme therapy and also through the use of the adenosine receptor antagonist theophylline, implicating both the nucleoside and its receptors in airway physiological alterations. All four adenosine receptors were expressed in the lungs of both control and partially ADA-deficient mice. However, transcript levels for the A(1), A(2B), and A(3) adenosine receptors were significantly elevated in partially ADA-deficient lungs. There was a significant increase in alveolar macrophages, and monocyte chemoattractant protein-3 was found to be elevated in the bronchial epithelium of these mice, which may have important implications in the regulation of pulmonary inflammation and airway hyperresponsiveness. Collectively, these findings suggest that elevations in adenosine can directly impact lung inflammation and physiology.
Chunn
J L
JL
Department of Biochemistry and Molecular Biology, University of Texas Health Science Center, Houston Medical School, Houston, TX 77030, USA.
Young
H W
HW
Banerjee
S K
SK
Colasurdo
G N
GN
Blackburn
M R
MR
D000241:Adenosine / Q000378:metabolism*; D000243:Adenosine Deaminase / Q000172:deficiency* / Q000627:therapeutic use; D000818:Animals; D001249:Asthma / Q000188:drug therapy / Q000276:immunology*; D001980:Bronchi / Q000276:immunology; D001991:Bronchitis / Q000188:drug therapy / Q000276:immunology; D002452:Cell Count; D054410:Chemokine CCL7; D016207:Cytokines; D004064:Digestive System / Q000201:enzymology; D004804:Eosinophils / Q000166:cytology; D008168:Lung / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D016676:Macrophages, Alveolar / Q000166:cytology; D008297:Male; D051379:Mice; D008817:Mice, Mutant Strains; D018945:Monocyte Chemoattractant Proteins / Q000235:genetics / Q000302:isolation & purification; D011014:Pneumonia / Q000188:drug therapy / Q000276:immunology; D012333:RNA, Messenger / Q000032:analysis; D018047:Receptors, Purinergic P1 / Q000235:genetics / Q000302:isolation & purification; D020545:Respiratory Mucosa / Q000276:immunology; D015398:Signal Transduction
C515451:Ccl7 protein, mouse; D054410:Chemokine CCL7; D016207:Cytokines; D018945:Monocyte Chemoattractant Proteins; D012333:RNA, Messenger; D018047:Receptors, Purinergic P1; D000243:Adenosine Deaminase; D000241:Adenosine